Cellular and molecular characterization of IDH1‐mutated diffuse low grade gliomas reveals tumor heterogeneity and absence of EGFR/PDGFRα activation

• Published in: Glia Vol. 66; no. 2; pp. 239 - 255
• Main Authors: Azar, S., Leventoux, N., Ripoll, C., Rigau, V., Gozé, C., Lorcy, F., Bauchet, L., Duffau, H., Guichet, P. O., Rothhut, B., Hugnot, J. P.
• Format: Journal Article
• Language: English
• Published: United States Wiley 01.02.2018
• Subjects: Adult; Animals; astrocytoma; Biomarkers, Tumor - genetics; Biomarkers, Tumor - metabolism; Brain Neoplasms - genetics; Brain Neoplasms - metabolism; Brain Neoplasms - pathology; diffuse low grade glioma; ERK; Female; Glioma - genetics; Glioma - metabolism; Glioma - pathology; Humans; IDH1 mutation; Isocitrate Dehydrogenase - genetics; Isocitrate Dehydrogenase - metabolism; Life Sciences; Male; Mice; Middle Aged; Mutation - genetics; Neoplasm Grading - methods; Neurons and Cognition; oligodendroglioma; Receptor, Epidermal Growth Factor - genetics; Receptor, Epidermal Growth Factor - metabolism; Receptor, Platelet-Derived Growth Factor alpha - genetics; Receptor, Platelet-Derived Growth Factor alpha - metabolism; Tumor Cells, Cultured; Young Adult; IDH1 mutation; diffuse low grade glioma; oligodendroglioma; astrocytoma; ERK
• ISSN: 0894-1491; 1098-1136
• DOI: 10.1002/glia.23240

Diffuse low grade gliomas (DLGG, grade II gliomas) are slowly‐growing brain tumors that often progress into high grade gliomas. Most tumors have a missense mutation for IDH1 combined with 1p19q codeletion in oligodendrogliomas or ATRX/TP53 mutations in astrocytomas. The phenotype of tumoral cells, their environment and the pathways activated in these tumors are still ill‐defined and are mainly based on genomics and transcriptomics analysis. Here we used freshly‐resected tumors to accurately characterize the tumoral cell population and their environment. In oligodendrogliomas, cells express the transcription factors MYT1, Nkx2.2, Olig1, Olig2, Sox8, four receptors (EGFR, PDGFRα, LIFR, PTPRZ1) but not the co‐receptor NG2 known to be expressed by oligodendrocyte progenitor cells. A variable fraction of cells also express the more mature oligodendrocytic markers NOGO‐A and MAG. DLGG cells are also stained for the young‐neuron marker doublecortin (Dcx) which is also observed in oligodendrocytic cells in nontumoral human brain. In astrocytomas, MYT1, PDGFRα, PTPRZ1 were less expressed whereas Sox9 was prominent over Sox8. The phenotype of DLGG cells is overall maintained in culture. Phospho‐array screening showed the absence of EGFR and PDGFRα phosphorylation in DLGG but revealed the strong activation of p44/42 MAPK/ERK which was present in a fraction of tumoral cells but also in nontumoral cells. These results provide evidence for the existence of close relationships between the cellular phenotype and the mutations found in DLGG. The slow proliferation of these tumors may be associated with the absence of activation of PDGFRα/EGFR receptors. Main Points IDH1‐mutated astrocytoma and oligodendroglioma cells express both common (Olig1/2, Nkx2.2, EGFR, LIFR, MAG, NOGO‐A) and preferentially‐expressed proteins (Sox8, Sox9, MYT1, PTPRZ1, PDGFRα, Dcx). EGFR & PDGFRα are not activated in these tumors.